Adams Wealth Management lowered its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 4.6% in the first quarter, HoldingsChannel.com reports. The fund owned 17,221 shares of the biopharmaceutical company’s stock after selling 822 shares during the quarter. Pfizer accounts for approximately 0.3% of Adams Wealth Management’s portfolio, making the stock its 27th biggest holding. Adams Wealth Management’s holdings in Pfizer were worth $892,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in PFE. Bank OZK increased its position in Pfizer by 0.3% during the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after acquiring an additional 195 shares during the period. TimeScale Financial Inc. increased its holdings in Pfizer by 2.9% in the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 196 shares during the period. Bath Savings Trust Co increased its holdings in Pfizer by 0.5% in the 4th quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after buying an additional 200 shares during the period. Fruth Investment Management increased its holdings in Pfizer by 0.7% in the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after buying an additional 200 shares during the period. Finally, Winfield Associates Inc. increased its holdings in Pfizer by 0.9% in the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after buying an additional 200 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s stock.
Several equities analysts have commented on PFE shares. Berenberg Bank set a $50.00 target price on shares of Pfizer in a report on Friday, May 27th. Wells Fargo & Company decreased their target price on shares of Pfizer from $60.00 to $55.00 in a report on Wednesday, May 4th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a report on Tuesday, May 3rd. Citigroup lifted their price target on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. Finally, Morgan Stanley began coverage on shares of Pfizer in a report on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.26.
Shares of NYSE PFE opened at $49.07 on Thursday. The company has a market capitalization of $275.33 billion, a P/E ratio of 11.25, a price-to-earnings-growth ratio of 0.56 and a beta of 0.76. Pfizer Inc. has a 52-week low of $38.82 and a 52-week high of $61.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company’s 50 day moving average price is $50.57 and its 200-day moving average price is $52.22.
Pfizer (NYSE:PFE – Get Rating) last issued its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.66 by ($0.04). The firm had revenue of $25.66 billion during the quarter, compared to analyst estimates of $24.73 billion. Pfizer had a return on equity of 38.29% and a net margin of 26.97%. The firm’s revenue for the quarter was up 76.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.93 EPS. Analysts forecast that Pfizer Inc. will post 6.61 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.26%. Pfizer’s dividend payout ratio is currently 36.70%.
In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the business’s stock in a transaction on Monday, May 16th. The shares were sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the sale, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP William R. Carapezzi, Jr. sold 32,908 shares of the business’s stock in a transaction on Thursday, May 12th. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company’s stock, valued at approximately $1,907,300. The disclosure for this sale can be found here. Insiders sold a total of 41,126 shares of company stock valued at $2,075,003 in the last quarter. 0.05% of the stock is currently owned by company insiders.
About Pfizer (Get Rating)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.